The Therapeutic Effect of Botulinum Toxin Type A on Trigeminal Neuralgia: Are There Any Differences between Type 1 versus Type 2 Trigeminal Neuralgia?

被引：6

作者：

Tereshko, Yan ^{[1
,2
]}

Valente, Mariarosaria ^{[1
,2
]}

Belgrado, Enrico ^{[3
]}

Dalla Torre, Chiara ^{[3
]}

Dal Bello, Simone ^{[1
]}

Merlino, Giovanni ^{[1
,2
]}

Gigli, Gian Luigi ^{[2
]}

Lettieri, Christian ^{[1
,2
]}

机构：

[1] Udine Univ Hosp, Clin Neurol Unit, Piazzale Santa Maria della Misericordia 15, I-33100 Udine, Italy

[2] Univ Udine, Dept Med DAME, Via Colugna 50, I-33100 Udine, Italy

[3] Udine Univ Hosp, Neurol Unit, Piazzale Santa Maria della Misericordia 15, I-33100 Udine, Italy

来源：

TOXINS | 2023年 / 15卷 / 11期

关键词：

trigeminal neuralgia; neuropathic pain; botulinum toxin type A; type 2 trigeminal neuralgia; type 1 trigeminal neuralgia; atypical trigeminal neuralgia; FACIAL-PAIN; MICROVASCULAR DECOMPRESSION; MULTIPLE-SCLEROSIS; TRPV1; EXPRESSION; SENSORY NEURONS; CLASSIFICATION; RELEASE; HYPERALGESIA; COMPRESSION; VIEW;

D O I：

10.3390/toxins15110654

中图分类号：

TS2 [食品工业];

学科分类号：

0832 ;

摘要：

Background: Botulinum toxin type A is an effective treatment for trigeminal neuralgia. Moreover, its efficacy in type 2 trigeminal neuralgia and comparative studies between type 1 and type 2 trigeminal neuralgia (TN) still need to be improved. Methods: We treated 40 TN patients with onabotulinumtoxinA; 18 had type 1 TN, and 22 had type 2 TN. We compared the baseline pain score with the Visual Analogue Scale (VAS) and paroxysm frequency (number per week) at the baseline with those obtained at 1-month and 3-month follow-ups. Nonetheless, we compared the baseline Penn Facial Pain Scale with the scores obtained at the 1-month follow-up. Results: BoNT/A effectively reduced pain intensity and frequency at the 1-month and 3-month follow-ups. Moreover, the type 1 TN and type 2 TN groups had baseline pain scores of 7.8 +/- 1.65 and 8.4 +/- 1.1, respectively. Pain significantly improved (p < 0.001) in both groups to 3.1 +/- 2.3 (type 1 TN) and 3.5 +/- 2.3 (type 2 TN) at the 1-month follow-up and to 3.2 +/- 2.5 (type 1 TN) and 3.6 +/- 2.5 (type 2 TN) at the 3-month follow-up. There was no difference between the two groups (p 0.345). The baseline paroxysm frequencies (number per week) were 86.7 +/- 69.3 and 88.9 +/- 62.2 for the type 1 and type 2 TN groups, respectively; they were significantly reduced in both groups at the 1-month and 3-month follow-ups without significant differences between the two groups (p 0.902). The Pain Facial Pain Scale improved at the 1-month follow-up, and no significant differences were found between the two groups. There was a strong correlation between background pain and paroxysm pain intensity (r 0.8, p < 0.001). Conclusions: Botulinum toxin type A effectively reduced the pain, paroxysm frequency, and PFPS scores of type 1 and type 2 trigeminal neuralgia patients without statistically significant differences. Facial asymmetry was the only adverse event.

引用

页数：16

共 73 条

[1] Treatment of multiple sclerosis-related trigeminal neuralgia with onabotulinumtoxinA [J].